Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024.Augurex’s poster, titled “Novel...
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1,...
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical...
Working in STEM means that you’re innovative, you’re creative, you’re passionate, you’re clever, you’re whoever you want to be. We’re so proud of our CEO Norma Biln being recognized by BC Business as a vital contributor to Women in Tech: Read Full...
